Thus, effective therapy and a new way of delivering therapeutic agents that can be safe in a larger comorbid stroke population and remain usable in multiple settings with or without IV-tPA/ET even after the therapeutic window are greatly needed. The gene discussed is PLAT; the disease is stroke disorder.